openPR Logo
Press release

Uncovering Novel Drug Candidates for Bipolar Depression: Market Forecast and Insights

07-05-2023 11:09 AM CET | Health & Medicine

Press release from: DelveInsight Business Research

Uncovering Novel Drug Candidates for Bipolar Depression:

The Latuda market forecast report provides analysis of Latuda market analysis and forecasts upto 2032 in the major markets. The comprehensive report provides analysis of Latuda market potential and Latuda market share analysis in Bipolar Depression across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2019 to 2032. It helps you to understand the Latuda mechanism of action, route of administration, dosage and development activities.

Download Sample Report to know the Latuda Market Share: Latuda Drug Market Forecast https://www.delveinsight.com/report-store/latuda-market-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

It presents a thorough description of Latuda's characteristics and its use specifically for Bipolar Depression, offering valuable insights into its market potential. The report provides rich insights with respect to the competition in the market as other emerging products that are in the advanced stage of pipeline development for Bipolar Depression are expected to give tough market competition to Latuda. It is predicted that the launch of late-stage emerging therapies in the near future will significantly impact the Bipolar Depression market.

Latuda Summary
LATUDA, which contains lurasidone hydrochloride as its active component, is an oral tablet. It has received approval in the United States for the treatment of bipolar depression in pediatric patients aged 10 to 17 years and for schizophrenia in adolescent and adult patients. It can be used as a standalone therapy or as an adjunctive treatment for bipolar depression in adults. In the European Union, LATUDA is only approved for treating schizophrenia, while in Japan, it has approval for both schizophrenia and bipolar disorder. Recently, Lupin Pharma obtained approval for a generic version of LATUDA, originally manufactured by Sunovion Pharmaceuticals. However, due to an agreement between the generic drug manufacturers and the manufacturer of LATUDA, generic versions of the medication are not currently available.

Stay ahead in competition by leveraging insights on Latuda market Report : Download Latuda Market Report https://www.delveinsight.com/report-store/latuda-market-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Facts of the Latuda Market Report:
• Leading Latuda for Bipolar Depression forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Latuda
• Thorough Latuda market forecast will help understand how drug is competing with other emerging Latuda
• Get analysis of the Latuda clinical trial advancements and the detailed clinical assessment, regulatory and commercial assessment
• The report also provides future market assessments for Latuda market forecast analysis for Bipolar Depression in the 7 Major Markets, Advance qualitative analysis like SWOT, expert analysts' views, detailed overview of market competitors, and short analysis of other emerging therapies in Bipolar Depression.

Request For Sample Report Here @ https://www.delveinsight.com/sample-request/latuda-market-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Related Reports By DelveInsight:
Bipolar Depression Market https://www.delveinsight.com/report-store/bipolar-disorder-manic-depression-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Bipolar Depression Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Bipolar Depression, historical and forecasted epidemiology as well as the Bipolar Depression market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Bipolar Depression Pipeline https://www.delveinsight.com/report-store/bipolar-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's, "Bipolar Depression - Pipeline Insight, 2023," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Bipolar Depression pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight Healthcare Consulting Services
DelveInsight's Healthcare Consulting Services offer a comprehensive and customized approach to address the diverse needs of clients in the healthcare sector. These services are specifically designed to tackle the most critical challenges faced by clients while also identifying and capitalizing on emerging opportunities.

By leveraging DelveInsight's deep industry knowledge, extensive market research capabilities, and advanced data analytics, the healthcare consulting services provide clients with practical and data-driven solutions. The consultants collaborate closely with clients to gain a thorough understanding of their unique requirements and obstacles, enabling them to develop tailored strategies and solutions. DelveInsight's consulting expertise encompasses various aspects of the healthcare industry, including market access, commercial strategy, product development, and regulatory affairs.

Get in touch today to navigate the complexities of the life sciences industry and successfully achieve your business goals. - https://www.delveinsight.com/consulting

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Uncovering Novel Drug Candidates for Bipolar Depression: Market Forecast and Insights here

News-ID: 3114155 • Views:

More Releases from DelveInsight Business Research

Vitiligo Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA Approvals, Future Outlook by DelveInsight
Vitiligo Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA App …
The "Vitiligo Pipeline Insight, 2025" report by DelveInsight delivers an in-depth view of the current clinical development scenario along with the future growth trajectory of the Vitiligo Market. As per DelveInsight's evaluation, the global Vitiligo treatment pipeline features 20+ leading companies actively engaged in developing 20+ therapeutic candidates. The analysis covers Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and developmental updates. The Vitiligo Pipeline report offers extensive commercial and clinical
Myelodysplastic Syndrome Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA Approvals, Future Outlook by DelveInsight
Myelodysplastic Syndrome Competitive Landscape 2025: Clinical Trial Analysis, Th …
DelveInsight's, "Myelodysplastic Syndrome Pipeline Insight 2025" report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Myelodysplastic Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Myelodysplastic Syndrome Pipeline Report • DelveInsight's Myelodysplastic Syndrome
Fibromyalgia Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA Approvals, Future Outlook by DelveInsight
Fibromyalgia Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA …
According to DelveInsight, the global Fibromyalgia pipeline features more than eight key companies actively developing over ten treatment candidates. The analysis encompasses ongoing clinical trials, therapeutic mechanisms of action, routes of administration, and recent developments within the Fibromyalgia treatment landscape. The Fibromyalgia Pipeline 2025 report provides an exhaustive evaluation of pipeline products, ranging from preclinical stages to marketed therapies. It includes comprehensive details on each drug's mechanism of action, clinical trial
Chronic Wounds Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA Approvals, Future Outlook by DelveInsight
Chronic Wounds Competitive Landscape 2025: Clinical Trial Analysis, Therapies, F …
As per DelveInsight's assessment, globally, Chronic Wounds pipeline constitutes 7+ key companies continuously working towards developing 8+ Chronic Wounds treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Chronic Wounds Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Wounds Market. The Chronic Wounds Pipeline report embraces in-depth commercial and clinical assessment

All 5 Releases


More Releases for Latuda

Bipolar Depression Market to Exceed USD 11.2 Billion by 2034
Bipolar disorder is a chronic psychiatric condition characterized by alternating episodes of mania/hypomania and depression. Among these, bipolar depression is more frequent, longer-lasting, and associated with greater functional impairment and suicide risk compared to mania. Managing bipolar depression remains a significant challenge, as traditional antidepressants can trigger manic episodes, and treatment options are limited. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71897 The bipolar depression market is expanding due to
Schizophrenia Market Outlook 2034 - Clinical Trials, Market Size, Medication, Pr …
Schizophrenia Market Size in the 7MM was approximately USD 7,972.0 million in 2022 and is projected to increase during the forecast period (2024-2034). Schizophrenia Market Summary In 2022, the US led the 7MM market, valued at USD 5.75 billion, with further growth expected by 2034. The Schizophrenia market is projected to grow steadily from 2024 to 2034, driven by rising disease awareness, improved diagnostics, and the development of more effective treatments. Schizophrenia
Neuroleptic Drugs Market Size, Share, Growth and Report 2024-2031 | Eli Lily and …
DataM Intelligence has released a new research report on the Neuroleptic Drugs market. The report provides a detailed analysis of current and emerging trends, offering insights into the market dynamics. It utilizes Porter's Five Forces model to assess key factors such as supplier and customer relationships, risks from various agents, competitive intensity, and opportunities for new entrants. The study also includes research data from various companies, analyzing factors like benefits,
Schizophrenia Market to Grow Positively at a Paltry CAGR During the Study Period …
DelveInsight's "Schizophrenia - Market Insight, Epidemiology and Market Forecast - 2034" report provides current treatment practices, emerging drugs, Schizophrenia market share of the individual therapies, current and forecasted Schizophrenia market size from 2020 to 2034 segmented by seven major markets. The report also offers current Schizophrenia therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the
Sunovion Pharmaceuticals "LATUDA market size expected to increase many folds by …
[Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on LATUDA (Sunovion Pharmaceuticals) providing insights into the drug market landscape and market forecast of LATUDA upto 2032. The report, titled "LATUDA Market Market Size, Forecast, and Drug Insight - 2032" is now available for review and analysis. Are you interested in finding out the projected market size of LATUDA in 2032? LATUDA
Schizophrenia Drugs Market Is Expected To Witness Faster Growth Throughout By Tr …
Acumen Research and Consulting has announced the addition of the "Schizophrenia Drugs Market” report to their offering. The Schizophrenia Drugs Market Report 2018 is an in depth study analyzing the current state of the Schizophrenia Drugs Market. It provides brief overview of the market focusing on definitions, market segmentation, end-use applications and industry chain analysis. The study on Schizophrenia Drugs Market provides analysis of China market covering the industry trends, recent